Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation

Transplantation. 2013 Aug 27;96(4):e26-9. doi: 10.1097/TP.0b013e31829d388d.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome
  • Complement C5 / antagonists & inhibitors*
  • Complement Factor H / genetics
  • Complement Inactivating Agents / therapeutic use
  • Female
  • Hemolytic-Uremic Syndrome / genetics
  • Hemolytic-Uremic Syndrome / immunology
  • Hemolytic-Uremic Syndrome / prevention & control*
  • Humans
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / immunology
  • Living Donors
  • Mutation, Missense
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • CFH protein, human
  • Complement C5
  • Complement Inactivating Agents
  • Complement Factor H
  • eculizumab